Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$919.21
-1.8%		$959.00
$661.85
▼
$1,072.75
$57.51B0.45334,429 shs333,870 shs
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$104.91
$103.67
$38.81
▼
$104.98
$20.03B1.413.55 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$190.01
+0.6%		$122.75
$22.28
▼
$208.90
$75.86B1.0911.94 million shs10.27 million shs
Natera, Inc. stock logo
NTRA
Natera
$410.35
+0.5%		$329.43
$160.59
▼
$427.47
$59.15B1.51.39 million shs2.16 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-2.39%-2.72%-8.99%-0.39%+21.98%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%0.00%0.00%0.00%+85.91%
Moderna, Inc. stock logo
MRNA
Moderna
-1.89%-3.02%+22.47%+136.89%+584.57%
Natera, Inc. stock logo
NTRA
Natera
-1.17%-0.08%+27.34%+46.24%+152.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$919.21
-1.8%		$959.00
$661.85
▼
$1,072.75
$57.51B0.45334,429 shs333,870 shs
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$104.91
$103.67
$38.81
▼
$104.98
$20.03B1.413.55 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$190.01
+0.6%		$122.75
$22.28
▼
$208.90
$75.86B1.0911.94 million shs10.27 million shs
Natera, Inc. stock logo
NTRA
Natera
$410.35
+0.5%		$329.43
$160.59
▼
$427.47
$59.15B1.51.39 million shs2.16 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-2.39%-2.72%-8.99%-0.39%+21.98%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%0.00%0.00%0.00%+85.91%
Moderna, Inc. stock logo
MRNA
Moderna
-1.89%-3.02%+22.47%+136.89%+584.57%
Natera, Inc. stock logo
NTRA
Natera
-1.17%-0.08%+27.34%+46.24%+152.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,158.6126.04% Upside
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.95
Reduce$98.21-6.38% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$77.83-59.04% Downside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$341.55-16.77% Downside

Current Analyst Ratings Breakdown

Latest EXAS, MRNA, ARGX, and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2026
Natera, Inc. stock logo
NTRA
Natera
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$360.00 ➝ $475.00
9/30/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$60.00 ➝ $80.00
9/25/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$350.00 ➝ $460.00
9/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Singular Research logo
Singular Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/22/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/9/2026
Natera, Inc. stock logo
NTRA
Natera
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $435.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Buy
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B13.54$20.45 per share44.95$118.34 per share7.77
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$3.25B6.17$1.27 per share82.83$12.58 per share8.34
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B39.02N/AN/A$22.14 per share8.58
Natera, Inc. stock logo
NTRA
Natera
$2.31B25.65N/AN/A$12.38 per share33.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0435.3024.660.9932.19%43.59%36.66%N/A
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A41,035.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)

Latest EXAS, MRNA, ARGX, and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.97
2.43
2.17
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
88.82%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.20%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Natera, Inc. stock logo
NTRA
Natera
5.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
7,200190.89 million188.60 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable

Recent News About These Companies

The Top HealthTech Questions Landing on Our Desks
September 30 at 7:06 AM  |  etftrends.comE
Natera (NASDAQ:NTRA) Hits New 12-Month High - Here's Why
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-natera-nasdaq-ntra-hits-new-12-month-high-heres-why-2026-09-28/
Natera (NTRA) Receives a Buy from Bernstein
September 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NTRA/pressreleases/4821726/natera-ntra-receives-a-buy-from-bernstein/
Natera (NASDAQ:NTRA) Stock Sees Heavy Put Option Buying
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053802
Natera, Inc. $NTRA Stock Acquired by QRG Capital Management Inc.
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-stock-acquired-by-qrg-capital-management-inc-2026-09-26/
Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says
September 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/natera-apos-signatera-genome-could-153003747.html
RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating
September 25, 2026  |  marketscreener.comM
Natera (NASDAQ:NTRA) Stock Sees Unusually High Put Option Buying
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-natera-nasdaq-ntra-stock-sees-unusually-high-put-option-buying-2026-09-25/
Natera (NASDAQ:NTRA) Stock Price Up 4% - Still a Buy?
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-natera-nasdaq-ntra-stock-price-up-4-still-a-buy-2026-09-24/
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar
September 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NTRA/pressreleases/4756445/stocks-making-big-moves-yesterday-autozone-natera-shopify-twilio-and-lennar/
Natera, Inc. - Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
September 23, 2026  |  marketscreener.comM
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
September 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2994666/natera-s-signatera-wins-japan-pmda-approval-as-bladder-cancer-cdx?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2994666
Why Is Natera (NTRA) Stock Soaring Today
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-natera-ntra-stock-soaring-213346274.html
3 Analysts, 3 Trades to Make Today
September 22, 2026  |  investorplace.comhttps://investorplace.com/2026/09/3-analysts-3-trades-to-make-today/
Natera, Inc. Receives Regulatory Approval in Japan for Signatera as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
September 22, 2026  |  marketscreener.comM
Natera, Inc. Receives Regulatory Approval in Japan for Signatera as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
September 22, 2026  |  marketscreener.comM
Goldman Sachs Keeps Their Hold Rating on Natera (NTRA)
September 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NTRA/pressreleases/4731070/goldman-sachs-keeps-their-hold-rating-on-natera-ntra/
Goldman Sachs Keeps Their Hold Rating on Natera (NTRA)
September 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NTRA/pressreleases/4731070/goldman-sachs-keeps-their-hold-rating-on-natera-ntra/
NTRA stock hits all-time high, OMER stock scales 5-year peak – what's driving investors' enthusiasm today?
September 22, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/ntra-stock-hits-all-time-high-omer-stock-scales-5-year-peak-whats-driving-investors-enthusiasm-today/ar-AA2cM2Li
NTRA stock hits all-time high, OMER stock scales 5-year peak – what's driving investors' enthusiasm today?
September 22, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/ntra-stock-hits-all-time-high-omer-stock-scales-5-year-peak-whats-driving-investors-enthusiasm-today/ar-AA2cM2Li
Andra AP fonden Boosts Stock Position in Natera, Inc. $NTRA
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-andra-ap-fonden-boosts-stock-position-in-natera-inc-ntra-2026-09-22/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Energy Transfer logo over a sunset scene with storage tanks, pipelines, and a refinery facility.
Energy Transfer Taps the AI Power Boom
By Peter Frank | September 23, 2026
Data center aisle with illuminated blue fiber optic cables connecting to server racks and network equipment.
Old Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom
By Jeffrey Neal Johnson | September 23, 2026
Exterior of a Texas Roadhouse restaurant at dusk with customers entering and a worker unloading boxes from a delivery truck.
Despite Record Sales, Texas Roadhouse Has Beef With Beef Costs
By Peter Frank | September 22, 2026
Exterior view of the Texas Stock Exchange (TXSE) building with glass facade, greenery, and city skyline in background.
Saddle Up: Texas Stock Exchange Ropes In $80 Billion in Listings
By Jeffrey Neal Johnson | October 2, 2026
argenex stock logo

argenex NASDAQ:ARGX

$919.21 -16.79 (-1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$919.26 +0.05 (+0.01%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Moderna stock logo

Moderna NASDAQ:MRNA

$190.01 +1.07 (+0.57%)
Closing price 04:00 PM Eastern
Extended Trading
$189.45 -0.56 (-0.29%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera stock logo

Natera NASDAQ:NTRA

$410.35 +1.88 (+0.46%)
Closing price 04:00 PM Eastern
Extended Trading
$411.84 +1.50 (+0.36%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas